Sotrovimab News and Research

RSS
The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

Bispecific antibody exhibits high breadth and potency against SARS-CoV-2 Omicron sub-lineages

What are the hidden sources of SARS-CoV-2 evolution?

What are the hidden sources of SARS-CoV-2 evolution?

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

Efficacy of monoclonal antibodies against Omicron BA.1, BA.2, and BA.5

Efficacy of monoclonal antibodies against Omicron BA.1, BA.2, and BA.5

Why Omicron is more infectious than other SARS-CoV-2 variants

Why Omicron is more infectious than other SARS-CoV-2 variants

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers report the detection of viral mutations associated with drug resistance in patients treated with REGEN-COV and sotrovimab

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

SARS-CoV-2 Omicron BA.5 tropism shifting back to ancestral strains

SARS-CoV-2 Omicron BA.5 tropism shifting back to ancestral strains

SARS-CoV-2 RBD vulnerability discovered - target for antibodies against variants

SARS-CoV-2 RBD vulnerability discovered - target for antibodies against variants

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Exploring antigenic traits of SARS-CoV-2 Omicron BA.5 and BA.4 subvariants

Exploring antigenic traits of SARS-CoV-2 Omicron BA.5 and BA.4 subvariants

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant